Optimum Recombinant Human Thyrotropin Dose in Patients with Differentiated Thyroid Carcinoma and End-Stage Renal Disease

Fabián Pitoia, Veronica Ilera, Maria Zanchetta, Adriana Foffano, Hugo Niepomniszcze
  • Endocrine Practice, November 2008, AACE Corp (American Association of Clinical Endocrinologists)
  • DOI: 10.4158/ep.14.8.961

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.4158/ep.14.8.961

The following have contributed to this page: Fabian Pitoia